Edition:
United Kingdom

Strides Shasun Ltd (STSA.NS)

STSA.NS on National Stock Exchange of India

403.20INR
23 May 2018
Change (% chg)

Rs11.15 (+2.84%)
Prev Close
Rs392.05
Open
Rs396.00
Day's High
Rs440.50
Day's Low
Rs396.00
Volume
24,064,339
Avg. Vol
1,292,519
52-wk High
Rs1,102.20
52-wk Low
Rs333.30

Chart for

About

Strides Shasun Limited, formerly Strides Arcolab Limited, is a vertically integrated global pharmaceutical company. The Company is engaged in the development and manufacturing of active pharmaceutical ingredients (APIs) and formulations, as well as biotech. Its business segments include Pharmaceutical and Biotech businesses. Its... (more)

Overall

Beta: 0.59
Market Cap(Mil.): Rs74,972.77
Shares Outstanding(Mil.): 89.49
Dividend: 4.50
Yield (%): 0.54

Financials

  STSA.NS Industry Sector
P/E (TTM): 21.94 30.95 32.75
EPS (TTM): 38.19 -- --
ROI: -- 14.84 14.38
ROE: -- 16.34 16.07

BRIEF-India's Strides Shasun Gets U.S. FDA Nod For Cinacalcet Hydrochloride Tablets

* STRIDES SHASUN RECEIVES USFDA APPROVAL FOR CINACALCET HYDROCHLORIDE TABLETS

02 May 2018

BRIEF-Strides Shasun To Divest Holding In Remaining API Asset At Ambernath

* SAYS TO DIVEST ITS HOLDING IN REMAINING API ASSET AT AMBERNATH TO SOLARA ACTIVE PHARMA SCIENCES LIMITED

24 Apr 2018

BRIEF-Strides Shasun Says NCLT Approves Co's Scheme Of Arrangement With Sequent Scientific And Solara Active Pharma Sciences

* SAYS NCLT APPROVED COMPOSITE SCHEME OF ARRANGEMENT BETWEEN CO, SEQUENT SCIENTIFIC AND SOLARA ACTIVE PHARMA SCIENCES Source text - http://bit.ly/2HLmsbG Further company coverage:

20 Apr 2018

BRIEF-India's Strides Shasun Gets U.S. FDA Nod For Cyproheptadine Hydrochloride Tablets

* GETS USFDA APPROVAL FOR CYPROHEPTADINE HYDROCHLORIDE TABLETS

12 Apr 2018

BRIEF-Strides Shasun Gets U.S. FDA Approval For Ibuprofen Softgel OTC Capsules

* SAYS CO GETS U.S. FDA APPROVAL FOR IBUPROFEN SOFTGEL OTC CAPSULES Source text - https://bit.ly/2Gu3qoC Further company coverage:

02 Apr 2018

BRIEF-Sequent Scientific Says NCLT ‍Approved Composite Scheme Between Co, Strides Shasun, Solara Active Pharma Sciences

* NCLT ‍APPROVED COMPOSITE SCHEME INVOLVING DEMERGER OF COMMODITY API BUSINESS OF STRIDES, HUMAN API BUSINESS OF CO INTO SOLARA Source text - http://bit.ly/2pyeydJ Further company coverage:

23 Mar 2018

BRIEF-Strides Shasun Gets U.S. FDA Approval For Efavirenz Tablet

* PRODUCT TO BE MANUFACTURED AT ORAL DOSAGE FACILITY AT BANGALORE; MARKETED BY STRIDES PHARMA INC IN U.S. MARKET Source text - http://bit.ly/2tKMrfZ Further company coverage:

14 Mar 2018

BRIEF-Strides Shasun Appoints Arun Kumar As Exec Chairman‍​

* SAYS APPOINTED ARUN KUMAR AS EXECUTIVE CHAIRMAN‍​ Source text: http://bit.ly/2Hqk1Kg Further company coverage:

12 Mar 2018

BRIEF-Strides Shasun To Launch Ranitidine Tablets In U.S.

* PRODUCT, TO BE LAUNCHED FOR U.S. MARKETS, WILL BE BACKWARD INTEGRATED AND MANUFACTURED AT JV’S ORAL DOSAGE FACILITY IN CHENNAI Source text: http://bit.ly/2tp4Yyk Further company coverage:

07 Mar 2018

BRIEF-Strides Shasun To Launch Ranitidine OTC Tablets In U.S.

* PRODUCT WILL BE MANUFACTURED AT THE JV'S (COMPANY'S 50:50 JV WITH VIVIMED LABS) ORAL DOSAGE FACILITY IN CHENNAI‍​ Source text: http://bit.ly/2oqiNHS Further company coverage:

26 Feb 2018

Earnings vs. Estimates